The Current Ratio as of November 2024 (TTM) for Kiniksa Pharmaceuticals, Ltd. (KNSA) is 3.24

According to Kiniksa Pharmaceuticals, Ltd.’s latest financial reports and current stock price. The company's current Current Ratio is 3.24. This represents a change of -15.57% compared to the average of 3.84 of the last 4 quarters.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Historical Current Ratio (quarterly & annually)

How has KNSA Current Ratio performed in the past?

The mean historical Current Ratio of Kiniksa Pharmaceuticals, Ltd. over the last ten years is 8.45. The current 3.24 Current Ratio has changed 3.74% with respect to the historical average. Over the past ten years (40 quarters), KNSA's Current Ratio was at its highest in in the June 2018 quarter at 15.72. The Current Ratio was at its lowest in in the March 2017 quarter at 0.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Kiniksa Pharmaceuticals, Ltd. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Average Current Ratio

How has KNSA Current Ratio performed in the past?

The current Current Ratio of Kiniksa Pharmaceuticals, Ltd. (KNSA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Kiniksa Pharmaceuticals, Ltd. (KNSA) Current Ratio vs. Peers

How is KNSA’s Current Ratio compared to its peers?

Kiniksa Pharmaceuticals, Ltd.’s Current Ratio is less than Nuvalent, Inc. (23.07), less than Ventyx Biosciences, Inc. (23.52), less than Arcellx, Inc. (4.29), less than Cullinan Oncology, Inc. (24.46), less than Day One Biopharmaceuticals, Inc. (14.62), less than Structure Therapeutics Inc. (27.63), less than Karuna Therapeutics, Inc. (19.31), less than Phathom Pharmaceuticals, Inc. (5.73), less than Replimune Group, Inc. (10.11), greater than Nuvectis Pharma, Inc. (2.74), less than Lyra Therapeutics, Inc. (3.64), less than Kronos Bio, Inc. (8.32), less than Gossamer Bio, Inc. (6.74), less than Cogent Biosciences, Inc. (6.44), less than Larimar Therapeutics, Inc. (13.10), less than Kura Oncology, Inc. (11.47), less than Cerevel Therapeutics Holdings, Inc. (10.22), greater than Spero Therapeutics, Inc. (2.68), greater than Bolt Biotherapeutics, Inc. (3.16), greater than Coherus BioSciences, Inc. (1.25), less than Gracell Biotechnologies Inc. (7.73), less than Neoleukin Therapeutics, Inc. (15.33),

Build a custom stock screener for Kiniksa Pharmaceuticals, Ltd. (KNSA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kiniksa Pharmaceuticals, Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kiniksa Pharmaceuticals, Ltd. (KNSA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kiniksa Pharmaceuticals, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.